June 1, 2026 – Patient Worthy

GSK’s Arexvy Gains Expanded Approval in Japan to Include Younger High-Risk Adults

Post author:Austin Newman
Post published:June 1, 2026
Post category:RSV

As reported by PharmaBiz, Japan’s Ministry of Health, Labour and Welfare (MHLW) has broadened the approved use of GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, to cover adults aged 18–49…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More